Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The aim was to explore whether the incidence of tonsillar squamous cell carcinomas (TSCCs) increased in Eastern Denmark, 2000-2010, and whether human papillomavirus (HPV) could explain the increase, and to assess the association of HPV prevalence with gender, age, and origin (i.e., the certainty of tonsillar tumor origin). We applied HPV DNA PCR and p16 immunohistochemistry to all TSCCs registered in the Danish Head and Neck Cancer Group (DAHANCA) and in the Danish Pathology Data Bank (n = 632). Pathologists reviewed and subdivided the tumors into two groups: specified and nonspecified TSCCs. Approximately 10% of HPV-positive tumors was genotyped by amplicon next-generation sequencing. The overall crude incidence of TSCCs increased significantly (2.7% per year) and was explained by an increasing incidence of HPV-positive TSCCs (4.9% per year). The overall HPV prevalence was 58%, with HPV16 being the predominant HPV type. In multivariate analysis, the HPV prevalence was associated with age (<55 vs. >60 years) (OR, 1.72; 95% CI 1.13-2.63) and origin (nonspecified vs. specified TSCCs) (OR, 0.15; 95% CI 0.11-0.22). The association of HPV prevalence with origin increased over time in specified TSCCs (OR per year, 1.10; 95% CI 1.01-1.19), whereas no change over time was observed among nonspecified TSCCs (OR per year, 0.99; 95% CI 0.90-1.08). In conclusion, the observed increase in the number of HPV-positive TSCCs can explain the increasing number of TSCCs in Eastern Denmark, 2000-2010. HPV prevalence was associated with younger age (<55 years) and a high certainty of tonsillar tumor origin.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29254DOI Listing

Publication Analysis

Top Keywords

hpv prevalence
24
eastern denmark
12
denmark 2000-2010
12
nonspecified tsccs
12
tsccs
10
hpv
9
tsccs increased
8
association hpv
8
hpv-positive tsccs
8
prevalence associated
8

Similar Publications

To compare HPV vaccination knowledge and non-adherence rates to cervical cancer screening in a nationally representative sample of American women before and following the COVID-19 pandemic, female participants aged 21-65 years from the National Cancer Institute Health Information National Trends Survey 2019 and 2022 were included. Adherence to cervical cancer screening was assessed based on the timing of their last Papanicolaou (PAP) smear, with participants classified as non-adherent to cervical cancer guidelines if their last PAP smear was > 3 years. Further, participants were asked about their knowledge of the HPV vaccine and were categorized as unaware if they had not heard of it before.

View Article and Find Full Text PDF

Purpose: Human papillomavirus (HPV) causes oral and anogenital cancers, the incidence of which is increasing. Late-stage diagnosis is associated with increased mortality. Neighborhood-level characteristics and distance to place of diagnosis may impact timely diagnosis.

View Article and Find Full Text PDF

Introduction: Human papillomavirus (HPV) infection has been implicated in autoimmune processes, yet concerns remain about the potential autoimmune risks of HPV vaccination. Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition that typically manifests in childhood. The relationship between HPV vaccination and the development of JIA remains uncertain.

View Article and Find Full Text PDF

Background: Mailed human papillomavirus (HPV) self-sampling kits improve cervical cancer screening adherence. The HOME trial found information needs and anxiety among HPV-positive patients. We designed a STEP trial to test optimized intervention strategies with bolstered educational materials and a centralized nurse communicating positive results.

View Article and Find Full Text PDF

Purpose: Early detection of HPV-associated oropharyngeal cancer (HPV+OPSCC), the most common HPV cancer in the United States, could reduce disease-related morbidity and mortality, yet currently, there are no early detection tests. Circulating tumor HPV DNA (ctHPVDNA) is a sensitive and specific biomarker for HPV+OPSCC at diagnosis. It is unknown if ctHPVDNA is detectable prior to diagnosis, and thus it's potential as an early detection test.

View Article and Find Full Text PDF